The Lancet Infectious Diseases
LightNews LightNews
banner
thelancetinfdis.bsky.social
The Lancet Infectious Diseases
@thelancetinfdis.bsky.social
2.2K followers 52 following 230 posts
The Lancet Infectious Diseases is the leading clinical infectious diseases journal for peer-reviewed research and review, comment, and news.

🌐 https://www.thelancet.com/journals/laninf/home
Posts Replies Media Videos
Pinned
thelancetinfdis.bsky.social
The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 19d
Read our November issue!

Featuring testing olorofim to treat fungal infections, introduction of nirsevimab for RSV in Chile, and new oxazolidinones for tuberculosis therapy.

www.thelancet.com/issue/S1473-...
thelancetinfdis.bsky.social
New Personal View

Post-tuberculosis lung disease: a case definition for use in research studies

www.thelancet.com/journals/lan...
Post-tuberculosis lung disease: a case definition for use in research studies
Despite growing awareness of the substantial burden of long-term pulmonary impairment among tuberculosis survivors, marked variability in how post-tuberculosis lung disease is defined across research ...
www.thelancet.com
November 11, 2025 at 8:13 AM
thelancetinfdis.bsky.social
New Review

British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases: 2025 update

www.thelancet.com/journals/lan...
British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases: 2025 update
The fungal diagnostic landscape is evolving; whereas previously, traditional culture-based methods dominated, most invasive fungal disease is now diagnosed with non-culture-based tests, including dire...
www.thelancet.com
November 11, 2025 at 8:12 AM
Reposted by The Lancet Infectious Diseases
lancetmicrobe.bsky.social
Our November issue is now online:

www.thelancet.com/journals/lan...

Our journal is #OpenAccess, so you are free to explore all of our content. But these hashtags offer a flavour: #HTLV-1 #AMR #Lassa #Neisseria #gonorrhoea #tuberculosis #TB #influenza

#IDSky #ClinMicro #OA
Cover of the November issue of The Lancet Microbe
November 8, 2025 at 9:38 PM
thelancetinfdis.bsky.social
New Comment

Negative results in long COVID clinical trials: choosing outcome measures for a heterogeneous disease

www.thelancet.com/journals/lan...
Negative results in long COVID clinical trials: choosing outcome measures for a heterogeneous disease
Long COVID is an umbrella term for the heterogeneous long-term consequences of SARS-CoV-2 infection. It encompasses a wide spectrum of phenotypes (sometimes overlapping), and its underlying mechanisms...
www.thelancet.com
November 9, 2025 at 7:52 PM
thelancetinfdis.bsky.social
New Research

Long-term consequences of monkeypox virus infection or modified vaccinia virus Ankara vaccination in Belgium (MPX-COHORT and POQS-FU-PLUS): a 24-month prospective and retrospective cohort study

www.thelancet.com/journals/lan...
Long-term consequences of monkeypox virus infection or modified vaccinia virus Ankara vaccination in Belgium (MPX-COHORT and POQS-FU-PLUS): a 24-month prospective and retrospective cohort study
Individuals previously infected with MPXV show strong and durable immunological memory lasting up to 2 years after infection, in contrast to the less robust and shorter-lived response observed after M...
www.thelancet.com
November 9, 2025 at 7:48 PM
thelancetinfdis.bsky.social
New Research

Immunogenicity and safety of an 18-month booster dose
of the VLA15 Lyme borreliosis vaccine candidate after primary
immunisation in children, adolescents, and adults in the USA:
a randomised, observer-blind, placebo-controlled, phase 2 trial

www.thelancet.com/journals/lan...
Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in children, adolescents, and adults in the USA: a randomised, observer...
The safety and robust anamnestic immune responses associated with VLA15 boosting support its use as a strategy to increase anti-OspA antibody levels before tick season among children, adolescents, and...
www.thelancet.com
November 9, 2025 at 7:46 PM
thelancetinfdis.bsky.social
New Research

Global, regional, and national burden of Chagas disease, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023

www.thelancet.com/journals/lan...
Global, regional, and national burden of Chagas disease, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
The GBD 2023 Chagas disease estimates are notably higher than previous GBD estimates, reflecting additional data and methodological improvements, and those published by the Pan American Health Organiz...
www.thelancet.com
November 5, 2025 at 8:35 AM
thelancetinfdis.bsky.social
New Review:

Kyasanur Forest disease: an emerging arboviral threat

www.thelancet.com/journals/lan...
Kyasanur Forest disease: an emerging arboviral threat
Kyasanur Forest disease is a neglected tick-borne viral haemorrhagic fever endemic to India's Western Ghats, caused by the Kyasanur Forest disease virus, a flavivirus transmitted by Haemaphysalis spin...
www.thelancet.com
November 5, 2025 at 8:34 AM
thelancetinfdis.bsky.social
New Comment

G20 2025: advancing equity and affordability in future tuberculosis vaccines for adolescents and adults

www.thelancet.com/journals/lan...
G20 2025: advancing equity and affordability in future tuberculosis vaccines for adolescents and adults
Ending tuberculosis is more than just a global health necessity; it is fundamental to sustainable development and global health security. With at least 10 million new cases and more than 1 million dea...
www.thelancet.com
November 5, 2025 at 8:32 AM
Reposted by The Lancet Infectious Diseases
lancetgh.bsky.social
The November issue is now live! www.thelancet.com/journals/lan...
Post-partum haemorrhage
www.thelancet.com/journals/lan...
Impact of breastfeeding on the global burden of NCDs in mothers and children www.thelancet.com/journals/lan...
Vaccine ecosystem in Africa www.thelancet.com/journals/lan...
The cover of the November 2025 issue of The Lancet Global Health, featuring a photograph of a group of African women seated on the ground and smiling. Some are breastfeding babies.
November 3, 2025 at 1:03 PM
thelancetinfdis.bsky.social
📅 Marco De Ambrogi will be attending ASTMH 2025, #TropMed25, November 9-13, 2025 in Toronto, Ontario, Canada on behalf of The Lancet Infectious Diseases!

📧Feel free to reach out with enquiries. Explore our scope, reach & impact, commitment to publishing excellence, & more: hubs.li/Q03BL6Th0
November 4, 2025 at 3:50 PM
Reposted by The Lancet Infectious Diseases
eclinicalmed.bsky.social
Derivation and external validation of community-acquired #pneumonia subphenotypes in Southeast Asia: a secondary analysis of prospective cohort studies

These subphenotypes may represent unique targets for future #CAP interventional trials

www.thelancet.com/journals/ecl...
#MedSky
October 29, 2025 at 12:08 PM
thelancetinfdis.bsky.social
New Research

Oral itraconazole versus oral voriconazole for treatment-naive patients with chronic pulmonary aspergillosis in India (VICTOR-CPA trial): a single-centre, open-label, randomised, controlled, superiority trial

www.thelancet.com/journals/lan...
Oral itraconazole versus oral voriconazole for treatment-naive patients with chronic pulmonary aspergillosis in India (VICTOR-CPA trial): a single-centre, open-label, randomised, controlled, superiori...
Voriconazole was not superior to itraconazole for treating chronic pulmonary aspergillosis and was associated with a significantly higher incidence of adverse events. Our findings support the continue...
www.thelancet.com
October 30, 2025 at 9:53 AM
thelancetinfdis.bsky.social
New Research

Vaccine effectiveness of a bivalent respiratory syncytial virus (RSV) pre-F vaccine against RSV-associated hospital admission among adults aged 75–79 years in England: a multicentre, test-negative, case–control study

www.thelancet.com/journals/lan...
Vaccine effectiveness of a bivalent respiratory syncytial virus (RSV) pre-F vaccine against RSV-associated hospital admission among adults aged 75–79 years in England: a multicentre, test-negative, ca...
This study provides evidence that the RSV pre-F vaccine is highly effective against RSV-associated hospital admissions, including exacerbations of chronic disease, and in adults with immunosuppression...
www.thelancet.com
October 28, 2025 at 10:04 AM
thelancetinfdis.bsky.social
New comment:

Tuberculosis and undernutrition: improving estimates to reinforce the policy imperative

www.thelancet.com/journals/lan...
Tuberculosis and undernutrition: improving estimates to reinforce the policy imperative
Undernutrition is a key driver of the global tuberculosis epidemic, increasing the risk of people developing tuberculosis disease and of poor outcomes in those who do.1 Each year, WHO publishes estima...
www.thelancet.com
October 28, 2025 at 10:01 AM
Reposted by The Lancet Infectious Diseases
thelancet.com
Community-acquired pneumonia is the leading infectious cause of morbidity and mortality globally.

Yet, there are several challenges associated with diagnosis, treatment, and long-term management of Community-acquired pneumonia.

Find out more in a new Seminar: tinyurl.com/hd2fwz7n
Figure showing the considerations for diagnosis and treatment initiation of patients with community-acquired pneumonia. Copyright: 2025 Elsevier Ltd. All rights are reserved.
October 20, 2025 at 2:47 PM
thelancetinfdis.bsky.social
New Personal View

Future-proofing tuberculosis therapy: framework for concurrent drug and resistance testing development

www.thelancet.com/journals/lan...
Future-proofing tuberculosis therapy: framework for concurrent drug and resistance testing development
The rapid emergence of resistance to novel tuberculosis drugs, such as bedaquiline, is a key threat to the long-term effectiveness of novel regimens. Given that the introduction of these agents has en...
www.thelancet.com
October 26, 2025 at 12:31 PM
thelancetinfdis.bsky.social
New podcast @steventong.bsky.social

Buzzsprout - www.buzzsprout.com/1740310/epis...

Apple - podcasts.apple.com/gb/podcast/i...

Spotify - open.spotify.com/episode/588l...
In Conversation with Steven Tong and Joshua Davis on adaptive platform trials - The Lancet Infectious Diseases in conversation with
Professors Steven Tong and Joshua Davis discuss all aspects of adaptive platform trials including advantages, disadvantages, differences from conventional trials, and tips for setting up and assessing...
www.buzzsprout.com
October 23, 2025 at 10:58 AM
thelancetinfdis.bsky.social
Read our November issue!

Featuring testing olorofim to treat fungal infections, introduction of nirsevimab for RSV in Chile, and new oxazolidinones for tuberculosis therapy.

www.thelancet.com/issue/S1473-...
October 23, 2025 at 8:55 AM
thelancetinfdis.bsky.social
New comment

Elimination of measles and rubella in Pacific island countries and areas

www.thelancet.com/journals/lan...
Elimination of measles and rubella in Pacific island countries and areas
Against the gloomy backdrop of a large-scale global measles resurgence in 2024–25, the announcement by WHO that all 21 Pacific island countries and areas (PICs) were verified to have eliminated endemi...
www.thelancet.com
October 22, 2025 at 4:13 PM
thelancetinfdis.bsky.social
📅 @phoebedownes.bsky.social will be attending ID Week, #IDWeek (19-22 October) in Atlanta, GA on behalf of The Lancet Infectious Diseases!

📧Feel free to reach out with enquiries. Explore our scope, reach & impact, commitment to publishing excellence, & more: hubs.li/Q03BL6Th0
October 13, 2025 at 11:26 AM
Reposted by The Lancet Infectious Diseases
lancetmicrobe.bsky.social
Our October issue is now online:

www.thelancet.com/journals/lan...

Our journal is #OpenAccess, so you are free to explore all of our content. But these hashtags offer a flavour: #Trypanosoma #Chagas #Streptococcus #AMR #gonorrhoea #cytomegalovirus #cholera #mpox #TB

#IDSky #ClinMicro #OA
Cover of The Lancet Microbe's October issue with a "Cytomegalovirus … image taken with transmission electron microscopy.
October 10, 2025 at 8:57 AM
thelancetinfdis.bsky.social
New Research

Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial

www.thelancet.com/journals/lan...
Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial
Both ensitrelvir and nirmatrelvir accelerate oropharyngeal SARS-CoV-2 viral clearance. Ensitrelvir is an effective alternative to currently available antivirals in treating COVID-19. Although COVID-19...
www.thelancet.com
October 13, 2025 at 7:45 AM
thelancetinfdis.bsky.social
New Review

Core outcome measurement set for clinical trials in dengue: an international Delphi consensus study (DEN-CORE)

www.thelancet.com/journals/lan...
Core outcome measurement set for clinical trials in dengue: an international Delphi consensus study (DEN-CORE)
Dengue, caused by any one of four distinct virus serotypes, is the most rapidly spreading mosquito-borne viral disease worldwide. It is a primary arboviral infection with increasing global incidence, ...
www.thelancet.com
October 8, 2025 at 10:57 AM
thelancetinfdis.bsky.social
New Review

The Emerging Resistance Index: tracking early resistance to new antibiotics

www.thelancet.com/journals/lan...
The Emerging Resistance Index: tracking early resistance to new antibiotics
The high clinical burden of antimicrobial resistance (AMR) and the dwindling antibiotic pipeline demand standardised tools to monitor resistance development to new antibiotics. The Emerging Resistance...
www.thelancet.com
October 8, 2025 at 10:55 AM